4-Antibody appoints ceo and new board member

To develop more partnerships with corporate pharma

Swiss antibody specialist 4-Antibody has appointed Robert Burns as chief executive and Thomas von Rüden to its board of directors.

Burns has previously held senior positions in the antibody area as ceo of Oslo, Norway-based Affitech and Celldex Therapeutics in the US.

Max Burger, 4-Antibody’s chairman, said Burns is a deal-maker and has the experience to drive 4-Antibody forward to achieve additional multi-target collaborations with corporate pharma to add to the partnership recently put in place with Boehringer Ingelheim.

Von Rüden was formerly ceo at Direvo Industrial Biotechnology in Cologne, Germany. Prior to this, he was chairman of Direvo’s Advisory Board and worked as president and ceo at Direvo Biotech until Bayer Schering acquired the company in September 2008.

Von Rüden also spent six years as cso and executive VP of Business Development with MorphoSys in Munich. Before that he was director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna.

‘We expect Thomas’s knowledge of key trends in pharma antibody discovery and development to add incremental momentum to our pursuit of new corporate partnerships as well as our internal drug discovery and development programmes,’ said Burns.

You may also like

Ingredients

4-Antibody to collaborate with HGS

To discover and develop fully human therapeutic antibodies
Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Long-term collaboration for targets in various disease indications
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Finance

Moderna partners with Recordati to commercialise propionic acidemia mRNA therapy

The pair have entered a strategic collaboration to advance and globally commercialise its investigational propionic acidemia treatment mRNA-3927, with Moderna leading clinical development and manufacturing and Recordati responsible for worldwide commercialisation
Subscribe now